Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.
1. A compound represented by Formula (IV) or a pharmaceutically acceptable salt thereof:
wherein:
R a is selected from the group consisting of:
1) Hydrogen;
2) Substituted or unsubstituted —C 1 -C 6 alkoxy;
3) Substituted or unsubstituted —C 1 -C 8 alkyl;
4) Substituted or unsubstituted —C 2 -C 8 alkenyl;
5) Substituted or unsubstituted —C 2 -C 8 alkynyl;
6) Substituted or unsubstituted arylalkyl;
7) Substituted or unsubstituted aryl; and
8) Substituted or unsubstituted C 3 -C 6 -cycloalkyl;
R b is selected from the group consisting of:
1) Hydrogen;
2) Substituted or unsubstituted —C 1 -C 8 alkyl;
3) Substituted or unsubstituted —C 2 -C 8 alkenyl;
4) Substituted or unsubstituted —C 2 -C 8 alkynyl;
5) Substituted or unsubstituted arylalkyl; and
6) Substituted or unsubstituted aryl;
or R a and R b are taken together with the nitrogen atom to which they are attached to form a heterocyclic ring; and
m is selected from 0, 1, 2 and 3.
2. A compound selected from the compounds set forth below, or a pharmaceutically acceptable salt thereof:
Example #
Structure
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
3. A method for treating a disease or condition selected from the group consisting of primary biliary cirrhosis, cerebrotendinous xanthomatosis, primary sclerosing cholangitis, alcoholic liver disease, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, atherosclerosis, hypercholesterolemia, hypertriglyceridemia, Type II diabetes, and hepatocellular carcinoma in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound according to claim 1 .
4. The method according to claim 3 , wherein the disease or condition is selected from the group consisting of primary biliary cirrhosis (PBC), nonalcoholic fatty liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH).
5. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.